Basic Information
| LncRNA/CircRNA Name | lncAGER |
| Synonyms | AGER-1 |
| Region | GRCh38_6:32180968-32184324 |
| Ensemble | ENSG00000204305 |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | programmed death 1 (PD-1)/programmed death ligand 1 (PD-1/PD-L1) | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | lung cancer |
| ICD-0-3 | C34 |
| Methods | qRT-PCR, western blotting, Luciferase reporter assay |
| Sample | lung cancer tissues, lung cancer cell lines (PC9, L78, A549, GLC-82, SBC-5, 95D, NCI-H460, NCI-H292 and NCI- H1395) |
| Expression Pattern | down-regulated |
| Function Description | LncAGER expression was moderately correlated with AGER expression underlying a mechanism that lncAGER upregulates AGER by competitively binding to miRNA-185. LncAGER was significantly down-regulated in 76.4% of lung cancer tissues compared to adjacent normal tissues due to promoter hypermethylation. Over-expression of the lncRNA resulted in significant decreases in proliferation rate, migration ability,colony formation efficiency of lung cancer cells and tumor growth in nude mice. |
| Pubmed ID | 29068471 |
| Year | 2017 |
| Title | Long non-coding RNA AGER-1 functionally upregulates the innate immunity gene AGER and approximates its anti-tumor effect in lung cancer. |
External Links
| Links for lncAGER | GenBank HGNC NONCODE |
| Links for lung cancer | OMIM COSMIC |